Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07023679
Recruiting Not applicable

Stellate Ganglion Morphine Infiltration on Myocardial I/R Injury

NCT07023679 · tracked via the Priya Life Science China tracker
Sponsor
The Second Hospital of Anhui Medical University
Phase
Not applicable
Started
2025-06-24
Last updated
2025-07-04

Condition(s) studied

Acute Myocardial Infarction (AMI)

Investigational drug(s) / intervention(s)

Morphine →saline placebo

Morphine: Morphine (10 mg, 10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization

saline placebo: Saline (10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization

Study summary

The goal of this clinical trial is to investigate whether morphine modulates the functions of the stellate ganglion to reduce myocardial ischemia/reperfusion (I/R) injury in AMI patients. It will also assess the safety of injecting morphine around the stellate ganglion via ultrasound guidance. The main questions it aims to answer are:

1\. Does morphine regulate stellate ganglion function to reduce myocardial I/R injury in AMI patients and improve one year outcome in AMI patients? 3. What medical problems do participants experience when receiving injected morphine around the stellate ganglion? Researchers will compare morphine to a placebo saline (as a control group) to determine whether stellate ganglion infiltration with morphine effectively treats patients with AMI following primary PCI.

Participants will:

* Receive a single injection of morphine or saline around the stellate ganglion.
* Evaluate the myocardial injury during their duration of hospital stay.
* Record their symptoms and any major adverse cardiovascular and cerebrovascular events within one year post-surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥18 years, Male or Female. * Acute ST-segment elevation myocardial infarction (STEMI) patients planned for percutaneous coronary intervention (PCI). Acute STEMI is defined as: electrocardiogram shows ST-segment elevation ≥0.2 mV in two or more adjacent leads, or new left bundle branch block (LBBW). * Within 24 hours of the onset of infarct-related chest pain. * Obtaining informed consent from the patient and their family. Exclusion Criteria: * Patients with severe complications of myocardial infarction, such as uncontrollable acute left heart failure and pulmonary edema, severe cardiogenic shock after cardiopulmonary resuscitation, severe mechanical complications including ventricular septal defect, papillary muscle rupture, and rupture of the left ventricular free wall; * Patients with old myocardial infarction, or cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs; * Patients with coagulation disorders due to systemic diseases and those who are currently using anticoagulants and are not suitable for injection; * Patients allergic to opioids or with a history of opioid addiction and those participating in other clinical studies; * Pregnant or breastfeeding women; * Patients with severe organ dysfunction or failure, such as liver failure, renal failure, and respiratory failure; * Patients with severe infections; * Patients with severe mental illness that cannot cooperate and those taking antipsychotic drugs; * Other patients considered unsuitable for this study by the researchers.

Primary outcome measure(s)

  • The incidence of major adverse cardiovascular and cerebrovascular events (MACCE) — within one year post-surgery
    The incidence of major adverse cardiovascular and cerebrovascular events (MACCE), defined as cardiac death, heart failure rehospitalization, recurrent myocardial infarction, coronary revascularization, and stroke, will be recorded within one year post-surgery.

Trial sites (2)

FacilityCityRegionStatus
The First Affiliated Hospital of Anhui Medical University Hefei China Recruiting
The Second Affiliated Hospital of Anhui Medical University Hefei China Recruiting

More The Second Hospital of Anhui Medical University trials in China

Transcranial Direct Current Stimulation for Depression Recruiting
Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage Recruiting
The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid Surgery Starting soon
Template-Guided Burr-Hole Drainage With Middle Meningeal Artery Coagulation for Chronic Subdural Hematoma Starting soon

Other trials for the same condition

Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction Recruiting
Trends and Risk Factors of Adverse Cardiovascular and Cerebrovascular Events After Primary PCI Recruiting
POCT Detection for Blood Concentration of Tirofiban in Acute Myocardial Infarction Based on Azo-POP Probe. Enrolling by invitation
Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction Recruiting
Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07023679 on ClinicalTrials.gov ↗ ← All trials in China